Healthcare technology company applying multimodal data and artificial intelligence to precision medicine, clinical care and therapeutics discovery.
Independent editorial and sponsored coverage are visibly separated. Sponsored company reports carry a clear commercial-relationship disclosure and remain subject to the same sourcing, byline, date and correction standards as other newsroom reports.
Tempus and Recursion have extended their data partnership through November 2029, set $42 million of committed payments over three years and added a worldwide license to Recursion’s TxFM RNA model.
Read full report →Send verifiable public material, a factual correction or a news tip to the editorial desk. Submissions are reviewed independently and do not guarantee publication.
